Gunderson Dettmer represented client Brightseed, a San Francisco-based developer of plant nutrient technology, in its $68 million Series B financing led by Temasek. Brightseed uses artificial intelligence to discover natural occurring compounds in plants to improve quality of life. The company will use its new capital to expand its research and development.

In the announcement of the transaction, CEO of Brightseed Jim Flatt said, "There is a lot to be gained by looking at traditional medicine. Our ancestors understood that nature did, in fact, offer a number of solutions to conditions. Think about things like aspirin, which came from the bark of the willow tree, and metformin, which came from the French lilac and is a first-line treatment for type II diabetes—those all originated in plants. This is a well-proven approach.”

The Gunderson deal team was led by Kirt Shuldberg and included Brendan McCarthy, Leanne Gould, Alex Lee, and Bettina Tiangco.

Companies:
Brightseed
Temasek